UCon-behandling av overaktiv blære (OAB) hos menn
Sikkerhet og ytelse av UCon for håndtering av ikke-neurogen OAB hos menn - en tidlig mulighetsstudie
UCon is a medical device for treatment of the symptoms of OAB and fecal incontinence (FI). It electrically stimulates the DGN through the skin to obtain modulated behaviour of the bladder musculature e.g., suppress undesired bladder activity to relieve the symptoms of the patient. This clinical investigation is a randomized, cross-over, single-site, prospective, early feasibility study, which is used to evaluate Ucon with respect to its initial clinical safety and device performance in a small number of males with OAB.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
The purpose of the current investigation is to obtain information about the type of stimulation that Ucon provide (time limited vs. urge stimulation), would be the most effective and feasible for the treatment of non-neurogenic OAB symptoms in males.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Dianna Mærsk Knudsen
- Telefonnummer: +45 40517712
- E-post: dmk@innoconmedical.dk
Studiesteder
-
-
-
Maastricht, Nederland
- Rekruttering
- Maastricht University Medical Center+
-
Ta kontakt med:
- John Heesakkers, MD
- Telefonnummer: +31 433877258
- E-post: john.heesakkers@mumc.nl
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Subject is ≥ 18 years of age.
- Subject is male.
- Subject is diagnosed with OAB
- Subject is able to communicate, provide feedback, understand and follow instructions during the course of the investigation.
Exclusion Criteria:
-
Subject is medically unstable (acute illness or complications of a chronic condition that might affect the subject's participation in the investigation).
-
Subject has a Post Void Residual (PVR) of more than 100 ml or a Bladder Voiding Efficiency (BVE) of less than 75% (measured by uroflowmetry as the ratio of voided volume (VV) and total bladder capacity (VV+PVR)).
-
Subject has an active infection in the genital area incl. skin infections and urinary tract infection.
-
Subject has had botulinum toxin (BOTOX) treatment in the pelvic region within 6 months.
-
Subject has used antimuscarinics or β3 agonists within 14 days weeks*.
-
Subject has an implanted pacemaker, implantable drug pump or other active medical device (any medical device that uses electrical energy or other source of power to make it function).
-
Subject is enrolled or planning to enrol in another clinical investigation or was enrolled in an investigational drug study or medical device investigation within four weeks to enrolment.
-
Subject has neuropathy to a degree that is presumed to diminish the effect of the electrical stimulation.
-
Subject has a history of cancer in the pelvic region, are currently receiving cancer treatment, or has radiation-induced damage to the pelvic region.
-
Subject has addictive behaviour defined as abuse of alcohol, cannabis, opioids, or other intoxicating drugs.
-
Subject does not speak and understand Dutch.
- If a subject is currently being treated with antimuscarinics or β3 agonists, he is allowed to be included in the investigation, however, a washout period of 14 days is required before baseline can be established.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Annen: Group A (Urge and Time limited)
The participant self-administer electrical stimulation to the dorsal genital nerve (DGN) using UCon with a stimulation mode that is activated for 60 seconds by the participant when he experience urgency (urge stimulation).The urge stimulation can be activated repeatedly during the day as the participant wears the device from morning to evening at home for 14 days. Following a stimulation wash-out period (14 days), the participants then stimulates with UCon for another 14 days using the time limited stimulation mode. |
Participants will receive stimulation for 60 seconds, when they feel an urgency.
Andre navn:
Participant will receive the stimulation as provided in time limited sessions (Range: 15 min - continuous), whenever it suits the participant during the day.
Andre navn:
|
|
Annen: Group B (Time limited and Urge)
The participant self-administer electrical stimulation to the dorsal genital nerve (DGN) using UCon with a stimulation mode that is activated for 30 minutes once a day, at a time that is convenient for the participant. The participant uses the device at home for 14 days. Following a stimulation wash-out period (14 days), the participant then stimulates with UCon for another 14 days using the urge stimulation mode. |
Participants will receive stimulation for 60 seconds, when they feel an urgency.
Andre navn:
Participant will receive the stimulation as provided in time limited sessions (Range: 15 min - continuous), whenever it suits the participant during the day.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
PRIMARY SAFETY: To evaluate adverse events [initial safety] of UCon for treatment of OAB symptoms in a home setting.
Tidsramme: After 44 days (end of study)
|
Characterization of adverse events and anticipated adverse device effects associated with the use of UCon during the investigational period. |
After 44 days (end of study)
|
|
PRIMARY PERFORMANCE: To evaluate the ratio of treatment change [performance] of OAB symptoms using UCon in a home setting
Tidsramme: Change from baseline at 14 days, 30 days and 44 days (study end)
|
Ratio of subjects with at least 50% change in their OAB symptoms from baseline. Participants shall complete a 3-day bladder diary to report their symptoms. The symptoms related to OAB:
|
Change from baseline at 14 days, 30 days and 44 days (study end)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
SECONDARY SAFETY: To identify the number of subjects experiencing adverse events associated with the use of UCon during the investigational period.
Tidsramme: After 44 days (end of study)
|
Number of subjects experiencing adverse events and anticipated adverse device effects. Subjects will report on any experience associated with the use of UCon. |
After 44 days (end of study)
|
|
SECONDARY SAFETY: To evaluate the severity of adverse events associated with the use of UCon during the investigational period.
Tidsramme: After 44 days (study end)
|
Severity of adverse events and anticipated adverse device effects.The severity will be evaluated from the subjects' report on any experience associated with the use of UCon. |
After 44 days (study end)
|
|
SECONDARY PERFORMANCE: To evaluate whether subjects using UCon experience a change in their quality of life.
Tidsramme: Change from baseline at 14 days and 44 days (end of study)
|
Ratio of subjects with a change in their OAB quality of life measures as assessed by specific QoL questionnaires related to OAB condition (ICIQ-OAB, AOBq). An overall score with greater values indicates a worse symptom outcome. |
Change from baseline at 14 days and 44 days (end of study)
|
|
SECONDARY PERFORMANCE: To evaluate whether subjects using UCon experience a change in their treatment outcome (i.e. symptoms) after therapy.
Tidsramme: Change from baseline at 14 days and 44 days (end of study)
|
Ratio of subjects with a change in their treatment outcome (i.e. symptoms) assessed by the 7-point Patient Global Impression of Improvement (PGI-I) scale. Higher scores indicates a worse treatment outcome. |
Change from baseline at 14 days and 44 days (end of study)
|
|
SECONDARY PERFORMANCE: To evaluate the device and treatment acceptability of UCon.
Tidsramme: After 44 days (study end)
|
Ratio of subjects that accept UCon and DGN stimulation as assessed by a satisfaction survey recorded after each stimulation period. |
After 44 days (study end)
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: John Heesakkers, MD, Maastricht UMC+, P. Debyelaan 25, 6229 HX Maastricht, The Netherlands
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Psykiske lidelser
- Mannlige urogenitale sykdommer
- Urologiske sykdommer
- Kvinnelige urogenitale sykdommer
- Kvinnelige urogenitale sykdommer og graviditetskomplikasjoner
- Vannlatingsforstyrrelser
- Nedre urinveissymptomer
- Urologiske manifestasjoner
- Atferdssymptomer
- Eliminasjonsforstyrrelser
- Patologiske tilstander, tegn og symptomer
- Oppførsel
- Tegn og symptomer
- Enuresis
- Urininkontinens
- Nattlig enurese
- Urininkontinens, Urge
- Nokturi
Andre studie-ID-numre
- NL_FEAS_01
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .